Loading...

Nippon Shinyaku Co., Ltd.

NPPNYPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$5.37
$0.00(0.00%)

Nippon Shinyaku Co., Ltd. (NPPNY) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for Nippon Shinyaku Co., Ltd. (NPPNY), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
8.08%
8.08%
Operating Income Growth
17.14%
17.14%
Net Income Growth
25.94%
25.94%
Operating Cash Flow Growth
121.78%
121.78%
Operating Margin
22.94%
22.94%
Gross Margin
68.10%
68.10%
Net Profit Margin
20.32%
20.32%
ROE
13.61%
13.61%
ROIC
14.51%
14.51%

Nippon Shinyaku Co., Ltd. (NPPNY) Income Statement & Financial Overview

Analyze Nippon Shinyaku Co., Ltd.’s NPPNY earnings with segmented quarterly and yearly financial statement figures.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$38.91B$41.99B$40.20B$39.13B
Cost of Revenue$12.31B$13.88B$12.30B$12.64B
Gross Profit$26.61B$28.11B$27.90B$26.50B
Gross Profit Ratio$0.68$0.67$0.69$0.68
R&D Expenses$10.79B$6.82B$9.23B$7.50B
SG&A Expenses$10.45B$9.53B$8.81B$9.22B
Operating Expenses$21.24B$16.35B$18.05B$16.72B
Total Costs & Expenses$33.55B$30.22B$30.34B$29.36B
Interest Income$56.00M$378.00M$33.00M$363.00M
Interest Expense$56.00M$24.00M$34.00M$31.00M
Depreciation & Amortization$1.49B$1.54B$1.52B$1.46B
EBITDA$4.25B$16.43B$8.31B$12.91B
EBITDA Ratio$0.11$0.39$0.21$0.33
Operating Income$5.36B$11.77B$9.86B$9.78B
Operating Income Ratio$0.14$0.28$0.25$0.25
Other Income/Expenses (Net)-$2.67B$3.47B-$3.07B$1.63B
Income Before Tax$2.70B$15.24B$6.79B$11.41B
Income Before Tax Ratio$0.07$0.36$0.17$0.29
Income Tax Expense-$1.31B$3.06B$678.00M$1.14B
Net Income$4.005B$12.18B$6.11B$10.26B
Net Income Ratio$0.10$0.29$0.15$0.26
EPS$59.48$180.76$90.68$152.39
Diluted EPS$59.45$180.76$90.68$152.39
Weighted Avg Shares Outstanding$67.39M$67.38M$67.37M$67.35M
Weighted Avg Shares Outstanding (Diluted)$67.39M$67.38M$67.37M$67.35M

Over the past four quarters, Nippon Shinyaku Co., Ltd. demonstrated steady revenue growth, increasing from $39.13B in Q1 2024 to $38.91B in Q4 2024. Operating income reached $5.36B in Q4 2024, maintaining a consistent 14% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $4.25B, reflecting operational efficiency. Net income dropped to $4.005B, with EPS at $59.48. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;